Publication

Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach

van Winkel, C. A. J., Moreno, A. & Curiel, D. T., Dec-2018, In : Molecular pharmaceutics. 15, 12, p. 5446-5453 8 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

van Winkel, C. A. J., Moreno, A., & Curiel, D. T. (2018). Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach. Molecular pharmaceutics, 15(12), 5446-5453. https://doi.org/10.1021/acs.molpharmaceut.8b00591

Author

van Winkel, Claudia A. J. ; Moreno, Alberto ; Curiel, David T. / Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach. In: Molecular pharmaceutics. 2018 ; Vol. 15, No. 12. pp. 5446-5453.

Harvard

van Winkel, CAJ, Moreno, A & Curiel, DT 2018, 'Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach', Molecular pharmaceutics, vol. 15, no. 12, pp. 5446-5453. https://doi.org/10.1021/acs.molpharmaceut.8b00591

Standard

Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach. / van Winkel, Claudia A. J.; Moreno, Alberto; Curiel, David T.

In: Molecular pharmaceutics, Vol. 15, No. 12, 12.2018, p. 5446-5453.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

van Winkel CAJ, Moreno A, Curiel DT. Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach. Molecular pharmaceutics. 2018 Dec;15(12):5446-5453. https://doi.org/10.1021/acs.molpharmaceut.8b00591


BibTeX

@article{3bc8731c458b4b9588c0ca618cb0809e,
title = "Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach",
abstract = "The adenovirus (Ad) is widely used as a vaccine because of its ability to induce a cellular and humoral immune response. In addition, human clinical trials have validated the safety and efficacy of Ad as a vaccine vector. The traditional approach for employing the adenovirus as vaccine is to configure the antigen genes into the expression cassette of the Ad genome. An alternative method for inducing an immune response is the {"}capsid-incorporation{"} strategy. This strategy is based upon the incorporation of proteins or peptides into the capsid proteins. This review will focus on the established uses of this approach as well as highlighting the new developments regarding the capsid-incorporation strategy.",
keywords = "vaccine, antigen, capsid incorporation, adenovirus, virus, capsid, epitope display, NEUTRALIZING ANTIBODIES, PROTEIN-IX, SEROTYPE 5, IMMUNITY, HEXON, INTERNALIZATION, DOMAIN",
author = "{van Winkel}, {Claudia A. J.} and Alberto Moreno and Curiel, {David T.}",
year = "2018",
month = "12",
doi = "10.1021/acs.molpharmaceut.8b00591",
language = "English",
volume = "15",
pages = "5446--5453",
journal = "Molecular pharmaceutics",
issn = "1543-8384",
publisher = "AMER CHEMICAL SOC INC",
number = "12",

}

RIS

TY - JOUR

T1 - Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach

AU - van Winkel, Claudia A. J.

AU - Moreno, Alberto

AU - Curiel, David T.

PY - 2018/12

Y1 - 2018/12

N2 - The adenovirus (Ad) is widely used as a vaccine because of its ability to induce a cellular and humoral immune response. In addition, human clinical trials have validated the safety and efficacy of Ad as a vaccine vector. The traditional approach for employing the adenovirus as vaccine is to configure the antigen genes into the expression cassette of the Ad genome. An alternative method for inducing an immune response is the "capsid-incorporation" strategy. This strategy is based upon the incorporation of proteins or peptides into the capsid proteins. This review will focus on the established uses of this approach as well as highlighting the new developments regarding the capsid-incorporation strategy.

AB - The adenovirus (Ad) is widely used as a vaccine because of its ability to induce a cellular and humoral immune response. In addition, human clinical trials have validated the safety and efficacy of Ad as a vaccine vector. The traditional approach for employing the adenovirus as vaccine is to configure the antigen genes into the expression cassette of the Ad genome. An alternative method for inducing an immune response is the "capsid-incorporation" strategy. This strategy is based upon the incorporation of proteins or peptides into the capsid proteins. This review will focus on the established uses of this approach as well as highlighting the new developments regarding the capsid-incorporation strategy.

KW - vaccine

KW - antigen

KW - capsid incorporation

KW - adenovirus

KW - virus

KW - capsid

KW - epitope display

KW - NEUTRALIZING ANTIBODIES

KW - PROTEIN-IX

KW - SEROTYPE 5

KW - IMMUNITY

KW - HEXON

KW - INTERNALIZATION

KW - DOMAIN

U2 - 10.1021/acs.molpharmaceut.8b00591

DO - 10.1021/acs.molpharmaceut.8b00591

M3 - Review article

VL - 15

SP - 5446

EP - 5453

JO - Molecular pharmaceutics

JF - Molecular pharmaceutics

SN - 1543-8384

IS - 12

ER -

ID: 76574464